Acurx Pharmaceuticals Inc

NASDAQ:ACXP  
4.25
+0.03 (+0.71%)
Products, Regulatory

Acurx Announces New Data From Phase 2A Clinical Trial Of C. Difficile Treatment

Published: 11/08/2021 13:33 GMT
Acurx Pharmaceuticals Inc (ACXP) - Acurx Announces New Microbiome Data From Its Phase 2a Clinical Trial of Ibezapolstat for Cdi at the 9th International C. Diff.
Conference.
Acurx Pharmaceuticals Inc - Results Support Expectation That Microbiome Effects May Be Predictive of Beneficial Outcomes, Low Rates of Recurrence.
Acurx Pharmaceuticals Inc - Phase 2b Trial Comparing Ibezapolstat to Vancomycin in Cdi Patients to Begin This Month.